Instead of using the liposomal formulation, we used fluorescently labeled lipid–peptide conjugate to evaluate the targeting effect of the compound to HER2 overexpressed cancer cells in vivo because nanocarriers themselves can accumulate specifically toward certain organs [53]. The gene discussed is ERBB2; the disease is cancer.